Paper65560
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.
Birkmayer W and 3 others. Lancet, 1977. Cited by 269 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Papers, record 65560. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/65560
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Benserazide | Major topic |
| Hydrazines | Major topic |
| Levodopa | Major topic |
| Monoamine Oxidase Inhibitors | Major topic |
| Parkinson Disease | Major topic |
| Phenethylamines | Major topic |
| Administration, Oral | |
| Aged | |
| Clinical Trials as Topic | |
| Disability Evaluation | |
| Drug Combinations | |
| Drug Evaluation | |
| Drug Synergism | |
| Drug Therapy, Combination | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Injections, Intravenous | |
| Male | |
| Time Factors |
Source PubMed
Cited by67
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 269 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,199,369 | Heterologous expression of hydroxylase coupled with pathway optimization enables highly efficient ʟ-DOPA production in Corynebacterium glutamicum. | Synth Syst Biotechnol | 2026 | https://conductscience.org/library/papers/42199369 | PubMed |
| 41,972,109 | Amantadine-based combination therapy of Parkinson's disease to prevent fluctuation and dyskinesia - experiences from a Parkinson outpatient clinic. | Front Aging Neurosci | 2026 | https://conductscience.org/library/papers/41972109 | PubMed |
| 40,650,193 | Parkinson Disease Signaling Pathways, Molecular Mechanisms, and Potential Therapeutic Strategies: A Comprehensive Review. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40650193 | PubMed |
| 37,796,288 | L-DOPA-therapy in Parkinson's disease: some personal reflections on L-DOPA therapy from Vienna and Berlin. | J Neural Transm (Vienna) | 2023 | https://conductscience.org/library/papers/37796288 | PubMed |
| 37,686,140 | Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37686140 | PubMed |
| 36,810,524 | Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/36810524 | PubMed |
| 35,622,265 | Garcinia morella extract confers dopaminergic neuroprotection by mitigating mitochondrial dysfunctions and inflammation in mouse model of Parkinson's disease. | Metab Brain Dis | 2022 | https://conductscience.org/library/papers/35622265 | PubMed |
| 35,394,205 | Treatment; Moussa B.H. Youdim. | J Neural Transm (Vienna) | 2022 | https://conductscience.org/library/papers/35394205 | PubMed |
| 35,110,492 | Recent Advances in Drug Therapy for Parkinson's Disease. | Intern Med | 2023 | https://conductscience.org/library/papers/35110492 | PubMed |
| 34,977,548 | Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson's disease. | Clin Park Relat Disord | 2022 | https://conductscience.org/library/papers/34977548 | PubMed |
| 31,974,721 | The discovery and development of rasagiline as a new anti-Parkinson medication. | J Neural Transm (Vienna) | 2020 | https://conductscience.org/library/papers/31974721 | PubMed |
| 31,562,557 | Selegiline: a molecule with innovative potential. | J Neural Transm (Vienna) | 2020 | https://conductscience.org/library/papers/31562557 | PubMed |
| 30,341,696 | Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. | J Neural Transm (Vienna) | 2018 | https://conductscience.org/library/papers/30341696 | PubMed |
| 29,417,334 | Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease. | J Neural Transm (Vienna) | 2018 | https://conductscience.org/library/papers/29417334 | PubMed |
| 29,387,272 | Effects on Sperms' Quality of Selegiline in Aged Rats. | Open Med Chem J | 2017 | https://conductscience.org/library/papers/29387272 | PubMed |
| 28,515,684 | Selegiline Ameliorates Depression-Like Behavior in Mice Lacking the CD157/BST1 Gene, a Risk Factor for Parkinson's Disease. | Front Behav Neurosci | 2017 | https://conductscience.org/library/papers/28515684 | PubMed |
| 27,763,504 | Neuroprotective Effect of the Marine-Derived Compound 11-Dehydrosinulariolide through DJ-1-Related Pathway in In Vitro and In Vivo Models of Parkinson's Disease. | Mar Drugs | 2016 | https://conductscience.org/library/papers/27763504 | PubMed |
| 27,480,491 | The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015). | Mol Psychiatry | 2016 | https://conductscience.org/library/papers/27480491 | PubMed |
| 27,252,617 | Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease. | Front Neurosci | 2016 | https://conductscience.org/library/papers/27252617 | PubMed |
| 27,145,762 | Nrf2: a modulator of Parkinson's disease? | J Neural Transm (Vienna) | 2016 | https://conductscience.org/library/papers/27145762 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/65560
GET https://conductscience.org/api/papers/v1/65560/cited_by?page=2